CTOs on the Move

Symbiomix Therapeutics

www.symbiomix.com

 
Symbiomix (sim-bye-OH-mix) is a late-stage, privately held biopharmaceutical company developing innovative medicines for serious women`s health infections that have been long neglected and are in need of new therapeutic options. Symbiomix was founded in 2012 by a team of experienced industry professionals and entrepreneurs and is backed by three of the world`s leading healthcare venture capital firms, OrbiMed, Fidelity Biosciences and HBM Partners. The Company`s lead product is SYM-1219, a novel drug candidate containing secnidazole, which is a next generation 5-nitroimidazole antibiotic. Symbiomix is based in New Jersey, with additional offices in Maryland and Connecticut.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.symbiomix.com
  • 105 Lock Street Suite 409
    Newark, NJ USA 07103-3576
  • Phone: 609.722.7250

Executives

Name Title Contact Details

Funding

Symbiomix Therapeutics raised $41M on 05/06/2015

Similar Companies

Osmotics

Osmotics is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Osmotics is based in Denver, CO. You can find more information on Osmotics at www.osmotics.com

Myocor

Myocor is a Osseo, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CRF Health

With operation centers in the United States and the United Kingdom and an R&D center of excellence in Finland, CRF Health is committed to driving the global change to higher-quality outcomes and more efficient paper-free clinical trials through improved patient engagement via intuitive and patient-focused eCOA (electronic Clinical Outcome Assessment) technology. By improving the process of conducting clinical studies, we help companies bring new medicines to market quickly, safely and more cost-effectively.

Histogenics

Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics` regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics` first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.

Tanita Corporation of America

Tanita Corporation of America, Inc. is a Arlington Heights, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.